SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Shares of Solid Biosciences (SLDB) have rallied 59.9% in the past month. The stock price increase was mainly due to positive initial data, announced in mid-Feb, from the early to mid-stage study of its next-generation gene therapy product candidate, SGT-003, for treating Duchenne muscular dystrophy (DMD).Interim biopsy data reported in the first three participants at day 90 showed an average microdystrophin expression of 110%, as measured by western blot, along with improvements in multiple biomarkers that ...